LAMAC 1/2
Alternative Names: LAMAC-1/2Latest Information Update: 15 Mar 2024
At a glance
- Originator Laminar Pharmaceuticals
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Infections
Most Recent Events
- 08 Mar 2024 Preclinical trials in Infections in Spain (unspecified route) prior to February 2024 (Laminar Pharmaceuticals pipeline, February 2024)
- 08 Mar 2024 Laminar Pharmaceuticals plans to launch LAMAC 1/2 in 2025 or 2026 (Laminar Pharmaceuticals pipeline, February 2024)